OncoNano Medicine

OncoNano uses its ON-BOARD nanotechnology platform to exploit the acidic tumor microenvironment and deliver therapeutic cargoes intratumorally. It is developing an oncology pipeline.

The company has a mission and work.

OncoNano is a clinical-stage oncology company working to transform cancer therapeutics with its proprietary nanotechnology platform

OncoNano Medicine partners with Gilead Sciences to assess its ON-BOARD™ encapsulation technology for delivering Gilead’s experimental drug candidate. The collaboration aims to evaluate whether the technology can improve the drug’s efficacy or targeting. Both companies specialize in advanced pharmaceutical solutions, with OncoNano focusing on nanoparticle-based delivery systems.

Jan 2026OncoNanoNews article

OncoNano Medicine appoints Brent Sorrells as Chief Operating Officer. Sorrells, with over 20 years of experience in biotechnology, joins to lead product development, strategic operations, and commercial execution for the company’s growth phase.

Nov 2025OncoNanoNews article

OncoNano Medicine reports first-in-human results for **ONM-501**, a dual-acting STING agonist, showing **durable tumor responses and prolonged stable disease** in patients with advanced solid tumors. Early data also highlight **complete responses in cutaneous squamous cell carcinoma** when combined with **Libtayo® (cemiplimab)**. The findings are presented at the **AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics**.

Oct 2025OncoNanoNews article

OncoNano Medicine names **Kartik Krishnan** as its new **Chief Executive Officer**. The company also promotes **Melissa Paoloni** to **Chief Operating Officer**, expanding its executive leadership team.

Mar 2024OncoNanoNews article